- Home
- AGMH vs TCRT Comparison
AGMH vs TCRT Comparison
Compare AGMH & TCRT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AGMH
- TCRT
- Stock Information
- Founded
- AGMH 2015
- TCRT 1998
- Country
- AGMH Hong Kong
- TCRT United States
- Employees
- AGMH N/A
- TCRT N/A
- Industry
- AGMH EDP Services
- TCRT Biotechnology: Pharmaceutical Preparations
- Sector
- AGMH Technology
- TCRT Health Care
- Exchange
- AGMH Nasdaq
- TCRT Nasdaq
- Market Cap
- AGMH 3.5M
- TCRT 3.8M
- IPO Year
- AGMH 2018
- TCRT N/A
- Fundamental
- Price
- AGMH $2.84
- TCRT $4.99
- Analyst Decision
- AGMH
- TCRT
- Analyst Count
- AGMH 0
- TCRT 0
- Target Price
- AGMH N/A
- TCRT N/A
- AVG Volume (30 Days)
- AGMH 616.9K
- TCRT 48.8K
- Earning Date
- AGMH 07-22-2025
- TCRT 08-13-2025
- Dividend Yield
- AGMH N/A
- TCRT N/A
- EPS Growth
- AGMH N/A
- TCRT N/A
- EPS
- AGMH 6.43
- TCRT N/A
- Revenue
- AGMH $32,044,575.00
- TCRT $11,000.00
- Revenue This Year
- AGMH N/A
- TCRT $5,680,500.00
- Revenue Next Year
- AGMH N/A
- TCRT N/A
- P/E Ratio
- AGMH $0.42
- TCRT N/A
- Revenue Growth
- AGMH N/A
- TCRT 83.33
- 52 Week Low
- AGMH $1.09
- TCRT $1.31
- 52 Week High
- AGMH $109.50
- TCRT $6.90
- Technical
- Relative Strength Index (RSI)
- AGMH 53.64
- TCRT 66.12
- Support Level
- AGMH $2.40
- TCRT $4.72
- Resistance Level
- AGMH $3.10
- TCRT $5.24
- Average True Range (ATR)
- AGMH 0.30
- TCRT 0.46
- MACD
- AGMH 0.12
- TCRT -0.02
- Stochastic Oscillator
- AGMH 85.58
- TCRT 66.89
About AGMH AGM Group Holdings Inc.
AGM Group Holdings Inc is an investment holding company. The company focuses on blockchain-oriented ASIC chip design; high-end crypto miner production and fintech technology software service. It generates maximum revenue from the sale of cryptocurrency mining machines and standardized computing equipment.
About TCRT Alaunos Therapeutics Inc.
Alaunos Therapeutics Inc is a clinical-stage cellular immuno-oncology company dedicated to the treatment of solid tumors through adoptive TCR-T cell therapy. It strikes cancer at its core by engineering cell therapies that target Neoantigens arising from genomic mutations. It has a single reportable and operating segment related to biopharmaceutical research and development.